An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment
Latest Information Update: 11 Nov 2022
At a glance
- Drugs Islatravir (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
Most Recent Events
- 08 Nov 2022 Results assessing he impact of renal impairment on the pharmacokinetics of islatravir in individuals with severe renal insufficiency, published in the Antimicrobial Agents and Chemotherapy.
- 21 Jul 2021 Results assessing safety and tolerability in individuals with severe renal insufficiency and healthy matched control presented at the 11th International AIDS Society Conference on HIV Science
- 28 Oct 2020 Status changed from active, no longer recruiting to completed.